Sfoglia per Autore
Recent advances in the molecular biology of systemic mastocytosis: Implications for diagnosis, prognosis, and therapy
2020 Martelli M.; Monaldi C.; De Santis S.; Bruno S.; Mancini M.; Cavo M.; Soverini S.
Targeting leukemic stem cells in chronic myeloid leukemia: Is it worth the effort?
2021 Soverini S.; De Santis S.; Monaldi C.; Bruno S.; Mancini M.
The role of hypoxic bone marrow microenvironment in acute myeloid leukemia and future therapeutic opportunities
2021 Bruno S.; Mancini M.; De Santis S.; Monaldi C.; Cavo M.; Soverini S.
Systemic mastocytosis: Molecular landscape and implications for treatment
2021 Monaldi C.; de Santis S.; Mancini M.; Bruno S.; Cavo M.; Soverini S.
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia
2021 Bruno S.; Bandini L.; Patuelli A.; Robustelli V.; Venturi C.; Mancini M.; Forte D.; De Santis S.; Monaldi C.; Grassi A.; Chiurumbolo G.; Paolini S.; Cristiano G.; Papayannidis C.; Sartor C.; Nanni J.; Ottaviani E.; Curti A.; Cavo M.; Soverini S.
Corrigendum: Denatonium as a Bitter Taste Receptor Agonist Modifies Transcriptomic Profile and Functions of Acute Myeloid Leukemia Cells (Front. Oncol, (2020), 10, (1225), 10.3389/fonc.2020.01225)
2021 Salvestrini V.; Ciciarello M.; Pensato V.; Simonetti G.; Laginestra M.A.; Bruno S.; Pazzaglia M.; De Marchi E.; Forte D.; Orecchioni S.; Martinelli G.; Bertolini F.; Mendez-Ferrer S.; Adinolfi E.; Di Virgilio F.; Cavo M.; Curti A.
Distinct profile of CD34+ cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease
2021 Forte D.; Barone M.; Morsiani C.; Simonetti G.; Fabbri F.; Bruno S.; Bandini E.; Sollazzo D.; Collura S.; Deregibus M.C.; Auteri G.; Ottaviani E.; Vianelli N.; Camussi G.; Franceschi C.; Capri M.; Palandri F.; Cavo M.; Catani L.
Synthesis of Novel Tryptamine Derivatives and Their Biological Activity as Antitumor Agents
2021 Simonetti G.; Boga C.; Durante J.; Micheletti G.; Telese D.; Caruana P.; Ghelli Luserna di Rora A.; Mantellini F.; Bruno S.; Martinelli G.; Calonghi N.
MPN-182 Droplet Digital PCR for Non-Invasive Detection of the KIT D816V Mutation in the Peripheral Blood of Patients With Suspected Systemic Mastocytosis
2022 Monaldi C.; de Santis S.; Mancini M.; Papayannidis C.; Sartor C.; Rondoni M.; Bruno S.; Cavo M.; Soverini S.
Combined Inhibition of Polo-like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells
2022 Mancini M.; Monaldi C.; De Santis S.; Rondoni M.; Papayannidis C.; Sartor C.; Curti A.; Bruno S.; Cavo M.; Soverini S.
CML-184 A Novel Droplet Digital PCR Strategy for Rapid and Sensitive Detection of BCR::ABL1 Kinase Domain Mutations Conferring Resistance to Second-Generation Tyrosine Kinase Inhibitors
2022 de Santis S.; Monaldi C.; Martelli M.; Mancini M.; Bruno S.; Castagnetti F.; Gugliotta G.; Polakova K.M.; Ernst T.; Maar D.; Corner A.; Cavo M.; Soverini S.
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors
2022 Mancini M.; De Santis S.; Monaldi C.; Castagnetti F.; Lonetti A.; Bruno S.; Dan E.; Sinigaglia B.; Rosti G.; Cavo M.; Gugliotta G.; Soverini S.
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia
2022 Soverini S.; De Santis S.; Martelli M.; Monaldi C.; Castagnetti F.; Gugliotta G.; Papayannidis C.; Mancini M.; Bruno S.; Venturi C.; Machova Polakova K.; Ernst T.; Maar D.; Corner A.; Cavo M.
Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia
2022 De Santis S.; Monaldi C.; Mancini M.; Bruno S.; Cavo M.; Soverini S.
CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies
2022 Bruno S.; Ghelli Luserna di Rora A.; Napolitano R.; Soverini S.; Martinelli G.; Simonetti G.
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted
2023 Mancini M.; Monaldi C.; De Santis S.; Papayannidis C.; Rondoni M.; Sartor C.; Bruno S.; Pagano L.; Criscuolo M.; Zanotti R.; Bonifacio M.; Tosi P.; Arock M.; Valent P.; Cavo M.; Soverini S.
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile